All In Biotech

Drug Trial Radar · NCT06471361

A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis

A Multicenter, Open-Label, Outpatient Study to Evaluate the Safe And Effective Use of a Zilucoplan Auto-Injector Combination Product for Subcutaneous Self-Administration by Study Participants With Generalized Myasthenia Gravis

Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

31

Actual

Start

Aug 27, 2024

Primary completion

Jan 28, 2025

Study completion Feb 3, 2025

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Jun 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effectiveness, safety and tolerability of zilucoplan auto-injector (ZLP-AI) self-administration.

Conditions

  • Generalized Myasthenia Gravis

Interventions

  • ZilucoplanDrug

    Zilucoplan will be self-administered subcutaneously by study participants at pre-specified time points.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Effective Self-administrations (SA) of Zilucoplan (ZLP) Using the Zilucoplan-auto-injector (ZLP-AI) From Visit 1 to Visit 8Time frame: From Visit 1 (Day 1) to Visit 8 (Day 14)

Locations

11 sites in 3 countries. Site status is shown where the registry gives one.

  • Dv0013 50628

    New Haven, Connecticut

  • Dv0013 50634

    Tampa, Florida

  • Dv0013 50648

    Columbia, Missouri

  • Dv0013 50556

    Chapel Hill, North Carolina

  • Dv0013 50635

    Columbus, Ohio

  • Dv0013 50555

    Austin, Texas

  • Dv0013 50636

    Greenfield, Wisconsin

  • Dv0013 40609

    Katowice, Poland

  • Dv0013 40759

    Krakow, Poland

  • Dv0013 40605

    Poznan, Poland

  • Dv0013 40760

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.